TrialHead & neck2023

Tumor immune microenvironment alterations using induction cetuximab in a phase II trial of deintensified therapy for p16-positive oropharynx cancer.

Joshua D Smith et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.